OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client demand Strengthens OXB’s global CDMO network and enhances service offering for existing and prospective clientsSupports existing near and medium-term financial guidance Oxford, UK – 7 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and ...